AngioDynamics (ANGO) Stock Forecast, Price & News

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.

1 brokers have issued 1 year price objectives for AngioDynamics' shares. Their ANGO share price forecasts range from $13.00 to $35.00. On average, they predict the company's share price to reach $24.00 in the next twelve months. This suggests a possible upside of 153.7% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.

AngioDynamics' stock was trading at $13.77 at the beginning of 2023. Since then, ANGO shares have decreased by 31.3% and is now trading at $9.46.
View the best growth stocks for 2023 here.

AngioDynamics saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 761,800 shares, a decrease of 7.1% from the April 30th total of 820,300 shares. Based on an average daily trading volume, of 334,300 shares, the short-interest ratio is presently 2.3 days. Approximately 2.0% of the company's stock are sold short.
View AngioDynamics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 11th 2023.
View our ANGO earnings forecast.

AngioDynamics, Inc. (NASDAQ:ANGO) issued its earnings results on Thursday, March, 30th. The medical instruments supplier reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.01) by $0.02. The medical instruments supplier had revenue of $80.70 million for the quarter, compared to the consensus estimate of $83.20 million. AngioDynamics had a negative trailing twelve-month return on equity of 0.71% and a negative net margin of 11.13%. The firm's revenue was up 9.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 EPS.

ETFs with the largest weight of AngioDynamics (NASDAQ:ANGO) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco Raymond James SB-1 Equity ETF (RYJ), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), Global X Aging Population ETF (AGNG), SPDR S&P Kensho New Economies Composite ETF (KOMP), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Medical Devices ETF (IHI).

AngioDynamics updated its FY 2023 earnings guidance on Friday, March, 31st. The company provided EPS guidance of -$0.06--$0.01 for the period, compared to the consensus EPS estimate of -$0.01. The company issued revenue guidance of $338.00 million-$342.00 million, compared to the consensus revenue estimate of $342.47 million.

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (18.57%), Victory Capital Management Inc. (9.86%), Dimensional Fund Advisors LP (6.33%), State Street Corp (5.29%), Systematic Financial Management LP (3.58%) and Paradigm Capital Management Inc. NY (2.22%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ANGO stock can currently be purchased for approximately $9.46.

AngioDynamics (NASDAQ:ANGO) has a market capitalization of $371.21 million and generates $316.22 million in revenue each year. The medical instruments supplier earns $-26,550,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis.

The company employs 800 workers across the globe.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The official website for the company is www.angiodynamics.com. The medical instruments supplier can be reached via phone at (518) 795-1400, via email at mpolyviou@evcgroup.com, or via fax at 518-795-1401.